SCHEMBL7143626

SCHEMBL7143626

CCCNCc1cccc(-c2cnc(-c3ccc(F)cc3)[nH]2)c1

nearest known ligand 0.45

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.45
HPGDS O60760 3/20 0.44
SCN2A Q99250 5/20 0.43
NPY5R Q15761 3/20 0.41
CNR2 P34972 4/20 0.40
CNR1 P21554 2/20 0.40
MAP3K8 P41279 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8110914 0.92 CYP1A2 (0.44) BACE1HPGDSSCN2ANPY5RCNR2
SCHEMBL7135108 0.91 CYP1A2 (0.46) BACE1HPGDSSCN2ANPY5RCNR2
SCHEMBL7179734 0.91 BACE1 (0.47) BACE1HPGDSSCN2ANPY5RCNR2
SCHEMBL7145535 0.91 SCN2A (0.52) HPGDSSCN2ANPY5RCNR2CNR1
SCHEMBL7140173 0.88 BACE1 (0.43) BACE1HPGDSSCN2ANPY5RCNR2
SCHEMBL7138181 0.88 HPGDS (0.49) BACE1HPGDSSCN2ANPY5R
SCHEMBL7141176 0.86 CYP1A2 (0.46) BACE1HPGDSSCN2ANPY5R
SCHEMBL7187293 0.85 BACE1 (0.44) BACE1HPGDSSCN2ANPY5RCNR2
SCHEMBL7138024 0.85 SSTR3 (0.47) BACE1HPGDSSCN2ANPY5R
SCHEMBL7145298 0.85 BACE1 (0.42) BACE1HPGDSSCN2ANPY5RCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed